Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
BackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinica...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1436183/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823858632340537344 |
|---|---|
| author | Shiyi Wang Xiaojian Wang Jing Ding Xudong Zhang Hongmei Zhu Yihong Fan Changbo Sun |
| author_facet | Shiyi Wang Xiaojian Wang Jing Ding Xudong Zhang Hongmei Zhu Yihong Fan Changbo Sun |
| author_sort | Shiyi Wang |
| collection | DOAJ |
| description | BackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinical efficacy. The long-term safety of upadacitinib in extensive populations remains unexplored. This study evaluates upadacitinib-related adverse events (AEs) utilizing data from the US Food and Drug Administration Adverse Event Reporting System (FAERS).MethodsWe employed disproportionality analyses, including the proportional reporting ratio (PRR), reporting odds ratio (ROR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM) algorithms to identify signals of upadacitinib-associated AEs for treating inflammatory bowel disease (IBD).ResultsFrom a total of 7,037,004 adverse event reports sourced from the FAERS database, 37,822 identified upadacitinib as the primary suspect drug in adverse drug events (ADEs), including 1,917 reports specifically related to the treatment of inflammatory bowel disease (IBD). The most commonly reported AEs were acne, product residue present, haematochezia, frequent bowel movements, flatulence, blood cholesterol increased, aligning with clinical trial outcomes. Notably, significant but unexpected AEs, such as rosacea, proctalgia, polyp, were also reported. Subgroup analysis indicated that the most prevalent AEs among the elderly included pulmonary embolism, cataract, and sepsis, whereas the 18–65 age group most frequently reported acne, abdominal pain, and nasopharyngitis. The median onset time for AEs related to upadacitinib was 41.00 days (interquartile range [IQR] 10–141.5 days), with the majority occurring within 3 months of treatment initiation (n = 269, 66.09%), particularly in the first month (n = 171, 42.01%).ConclusionOur findings affirm clinical observations and reveal potential new AE signals for upadacitinib, underscoring the need for prospective clinical studies to verify these results and clarify their clinical relevance. This study contributes valuable evidence for ongoing safety evaluations of upadacitinib. |
| format | Article |
| id | doaj-art-8c996fe8f2c64d77aa565c42e96e11dd |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-8c996fe8f2c64d77aa565c42e96e11dd2025-02-11T10:36:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.14361831436183Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting systemShiyi Wang0Xiaojian Wang1Jing Ding2Xudong Zhang3Hongmei Zhu4Yihong Fan5Changbo Sun6Department of Gastroenterology, Ningbo Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo, ChinaDepartment of Gastroenterology, Ningbo Medical Center LiHuiLi Hospital, Ningbo, ChinaDepartment of Gastroenterology, Ningbo Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo, ChinaDepartment of Gastroenterology, Ningbo Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo, ChinaDepartment of Gastroenterology, Ningbo Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo, ChinaDepartment of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Gastroenterology, Ningbo Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo, ChinaBackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinical efficacy. The long-term safety of upadacitinib in extensive populations remains unexplored. This study evaluates upadacitinib-related adverse events (AEs) utilizing data from the US Food and Drug Administration Adverse Event Reporting System (FAERS).MethodsWe employed disproportionality analyses, including the proportional reporting ratio (PRR), reporting odds ratio (ROR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM) algorithms to identify signals of upadacitinib-associated AEs for treating inflammatory bowel disease (IBD).ResultsFrom a total of 7,037,004 adverse event reports sourced from the FAERS database, 37,822 identified upadacitinib as the primary suspect drug in adverse drug events (ADEs), including 1,917 reports specifically related to the treatment of inflammatory bowel disease (IBD). The most commonly reported AEs were acne, product residue present, haematochezia, frequent bowel movements, flatulence, blood cholesterol increased, aligning with clinical trial outcomes. Notably, significant but unexpected AEs, such as rosacea, proctalgia, polyp, were also reported. Subgroup analysis indicated that the most prevalent AEs among the elderly included pulmonary embolism, cataract, and sepsis, whereas the 18–65 age group most frequently reported acne, abdominal pain, and nasopharyngitis. The median onset time for AEs related to upadacitinib was 41.00 days (interquartile range [IQR] 10–141.5 days), with the majority occurring within 3 months of treatment initiation (n = 269, 66.09%), particularly in the first month (n = 171, 42.01%).ConclusionOur findings affirm clinical observations and reveal potential new AE signals for upadacitinib, underscoring the need for prospective clinical studies to verify these results and clarify their clinical relevance. This study contributes valuable evidence for ongoing safety evaluations of upadacitinib.https://www.frontiersin.org/articles/10.3389/fphar.2025.1436183/fullupadacitinibadverse eventFAERSpharmacovigilancedata mining |
| spellingShingle | Shiyi Wang Xiaojian Wang Jing Ding Xudong Zhang Hongmei Zhu Yihong Fan Changbo Sun Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system Frontiers in Pharmacology upadacitinib adverse event FAERS pharmacovigilance data mining |
| title | Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system |
| title_full | Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system |
| title_fullStr | Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system |
| title_full_unstemmed | Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system |
| title_short | Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system |
| title_sort | disproportionality analysis of upadacitinib related adverse events in inflammatory bowel disease using the fda adverse event reporting system |
| topic | upadacitinib adverse event FAERS pharmacovigilance data mining |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1436183/full |
| work_keys_str_mv | AT shiyiwang disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem AT xiaojianwang disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem AT jingding disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem AT xudongzhang disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem AT hongmeizhu disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem AT yihongfan disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem AT changbosun disproportionalityanalysisofupadacitinibrelatedadverseeventsininflammatoryboweldiseaseusingthefdaadverseeventreportingsystem |